Your browser is no longer supported. Please, upgrade your browser.
Quidel Corporation
Index- P/E7.23 EPS (ttm)20.40 Insider Own1.40% Shs Outstand41.73M Perf Week1.93%
Market Cap5.84B Forward P/E20.79 EPS next Y7.10 Insider Trans-1.10% Shs Float36.63M Perf Month11.14%
Income883.00M PEG1.00 EPS next Q1.55 Inst Own87.90% Short Float10.43% Perf Quarter14.43%
Sales1.87B P/S3.12 EPS this Y971.80% Inst Trans-5.67% Short Ratio7.39 Perf Half Y36.28%
Book/sh39.16 P/B3.77 EPS next Y-53.47% ROA44.80% Target Price137.25 Perf Year-24.35%
Cash/sh14.62 P/C10.09 EPS next 5Y7.20% ROE60.20% 52W Range103.31 - 265.00 Perf YTD-17.86%
Dividend- P/FCF9.20 EPS past 5Y154.30% ROI61.30% 52W High-45.28% Beta-0.22
Dividend %- Quick Ratio3.20 Sales past 5Y53.30% Gross Margin79.30% 52W Low40.37% ATR8.00
Employees1370 Current Ratio3.90 Sales Q/Q7.10% Oper. Margin61.30% RSI (14)53.87 Volatility7.02% 5.68%
OptionableYes Debt/Eq0.00 EPS Q/Q-4.60% Profit Margin47.20% Rel Volume0.67 Prev Close147.56
ShortableYes LT Debt/Eq0.00 EarningsNov 04 AMC Payout0.00% Avg Volume516.85K Price145.01
Recom2.50 SMA204.48% SMA505.12% SMA2009.84% Volume258,446 Change-1.72%
Jan-22-21Upgrade Raymond James Mkt Perform → Outperform $250
May-12-20Downgrade JP Morgan Neutral → Underweight $120 → $158
Mar-26-20Downgrade Barclays Overweight → Equal Weight $90
Oct-23-18Resumed Raymond James Strong Buy $80
Mar-08-18Upgrade Raymond James Outperform → Strong Buy
Jan-22-18Reiterated Barclays Overweight $50 → $60
Jan-04-18Upgrade CL King Neutral → Buy
Sep-19-17Upgrade Piper Jaffray Neutral → Overweight
Jul-18-17Upgrade William Blair Mkt Perform → Outperform
Jul-18-17Upgrade Canaccord Genuity Hold → Buy $25 → $42
Apr-25-17Reiterated Canaccord Genuity Hold $24 → $24.50
Feb-17-17Initiated CL King Neutral
Dec-16-16Downgrade Piper Jaffray Overweight → Neutral
Jun-13-16Upgrade Raymond James Mkt Perform → Outperform
Feb-18-16Reiterated Barclays Overweight $28 → $22
Feb-09-16Downgrade Canaccord Genuity Buy → Hold $22 → $18
Jan-08-16Reiterated Canaccord Genuity Buy $25 → $22
Dec-14-15Downgrade Raymond James Outperform → Mkt Perform
Sep-02-15Initiated Barclays Overweight $28
Jul-31-13Reiterated Canaccord Genuity Buy $30 → $35
Nov-30-21 04:10PM  
Nov-26-21 05:07PM  
Nov-19-21 06:00PM  
Nov-16-21 11:58AM  
Nov-05-21 12:54PM  
Nov-04-21 08:56PM  
Nov-02-21 12:44PM  
Oct-29-21 11:47AM  
Oct-28-21 03:05PM  
Oct-20-21 05:30PM  
Oct-18-21 03:11PM  
Oct-15-21 09:10AM  
Oct-14-21 06:10AM  
Oct-11-21 09:44AM  
Oct-08-21 01:08PM  
Oct-07-21 07:16PM  
Oct-06-21 09:14AM  
Oct-05-21 07:00AM  
Oct-02-21 08:45AM  
Oct-01-21 11:39AM  
Sep-14-21 09:58AM  
Sep-03-21 10:44AM  
Sep-02-21 06:03PM  
Sep-01-21 04:10PM  
Aug-27-21 07:00AM  
Aug-25-21 11:31AM  
Aug-18-21 01:28PM  
Aug-17-21 12:13PM  
Aug-10-21 09:00AM  
Aug-06-21 03:09PM  
Aug-05-21 11:01PM  
Aug-03-21 12:30PM  
Jul-29-21 03:05PM  
Jul-28-21 07:49AM  
Jul-26-21 08:30AM  
Jul-19-21 04:29PM  
Jul-14-21 04:10PM  
Jul-13-21 11:03AM  
Jul-12-21 09:15AM  
Jul-08-21 05:50PM  
Jul-01-21 05:50PM  
Jun-30-21 01:43AM  
Jun-29-21 06:29PM  
Jun-24-21 05:50PM  
Jun-21-21 07:30AM  
Jun-19-21 06:02AM  
Jun-18-21 05:45PM  
Jun-16-21 05:50PM  
Jun-14-21 08:42AM  
Jun-13-21 05:18AM  
Jun-11-21 04:10PM  
Jun-10-21 04:45PM  
Jun-09-21 05:45PM  
Jun-07-21 11:11AM  
May-29-21 06:40AM  
May-24-21 05:10PM  
May-23-21 04:08AM  
May-14-21 04:10PM  
May-07-21 01:58PM  
May-06-21 08:55PM  
May-05-21 08:30PM  
May-04-21 06:00PM  
May-01-21 10:17AM  
Apr-30-21 09:55AM  
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology worldwide. It offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a POC products to detect infectious and inflammatory diseases and conditions of the eye. The company also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, it offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, the company provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, it offers Lyra molecular real-time polymerase chain reaction assays; Solana, an amplification and detection system; and Virena, a wireless cellular data management and surveillance system The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail and urgent care clinics, pharmacies, and wellness screening centers. Quidel Corporation was incorporated in 1979 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
POLAN MARY LAKE PH DDirectorSep 03Sale141.716,167873,91319,687Sep 08 07:56 PM
Kroll WernerSVP, R&DJul 01Option Exercise0.00982011,229Jul 02 06:08 PM
Ferenczy William J.SVP, Cardio/Metabolic UnitJun 12Option Exercise0.002,00007,324Jun 16 08:23 PM
Kroll WernerSVP, R&DMay 27Option Exercise0.004,376012,495Jun 01 07:56 PM
WIDDER KENNETH JDirectorMay 16Option Exercise0.00576016,032May 18 08:00 PM
POLAN MARY LAKE PH DDirectorMay 16Option Exercise0.00485025,854May 18 07:59 PM
SLACIK CHARLES PDirectorMay 14Option Exercise0.00734012,199May 14 08:12 PM
SLACIK CHARLES PDirectorMay 13Sale113.261,000113,25811,465May 14 08:12 PM
Wilkins Joseph D Jr.DirectorMay 12Option Exercise0.002890289May 14 08:22 PM
WIDDER KENNETH JDirectorMay 12Option Exercise0.001,040015,456May 14 08:19 PM
Strobeck MatthewDirectorMay 12Option Exercise0.001,04004,909May 14 08:15 PM
SLACIK CHARLES PDirectorMay 12Option Exercise0.001,250012,465May 14 08:12 PM
RHOADS ANN DDirectorMay 12Option Exercise0.006240624May 14 08:10 PM
POLAN MARY LAKE PH DDirectorMay 12Option Exercise0.001,040025,369May 14 08:09 PM
ORDONEZ KATHYDirectorMay 12Option Exercise0.001,04002,896May 14 08:08 PM
Michael Edward L.DirectorMay 12Option Exercise0.001,04007,474May 14 08:06 PM
BUECHLER KENNETH FDirectorMay 12Option Exercise0.001,040060,864May 14 08:05 PM
Ferenczy William J.SVP, Cardio/Metabolic UnitMay 03Option Exercise23.4180318,7986,127May 04 07:45 PM
Ferenczy William J.SVP, Cardio/Metabolic UnitMay 03Sale105.7480384,9095,324May 04 07:45 PM
Ferenczy William J.SVP, Cardio/Metabolic UnitMar 17Option Exercise16.604,60176,39012,506Mar 19 07:55 PM
Ferenczy William J.SVP, Cardio/Metabolic UnitMar 17Sale136.067,4001,006,8375,106Mar 19 07:55 PM
Kroll WernerSVP, R&DFeb 24Sale173.715,283917,7348,119Feb 24 07:53 PM
Kroll WernerSVP, R&DFeb 23Sale166.304,835804,05813,402Feb 24 07:53 PM
Kroll WernerSVP, R&DFeb 22Option Exercise43.5412,784556,67431,021Feb 24 07:53 PM
BRYANT DOUGLAS CPresident & CEOFeb 22Buy165.305,000826,500495,807Feb 22 07:40 PM
Kroll WernerSVP, R&DFeb 22Sale164.1112,7842,097,95518,237Feb 24 07:53 PM